These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33809369)

  • 21. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.
    Liu Y; Liu Z; Yang Y; Cui J; Sun J; Liu Y
    Br J Cancer; 2023 Oct; 129(7):1041-1049. PubMed ID: 37452117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.
    Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H
    Front Immunol; 2020; 11():622509. PubMed ID: 33633741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
    Mylvaganam G; Yanez AG; Maus M; Walker BD
    Front Immunol; 2019; 10():2109. PubMed ID: 31552045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replicating viral vector platform exploits alarmin signals for potent CD8
    Kallert SM; Darbre S; Bonilla WV; Kreutzfeldt M; Page N; Müller P; Kreuzaler M; Lu M; Favre S; Kreppel F; Löhning M; Luther SA; Zippelius A; Merkler D; Pinschewer DD
    Nat Commun; 2017 May; 8():15327. PubMed ID: 28548102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
    Melief CJ; Kast WM
    Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
    Liu M; Zhou J; Chen Z; Cheng AS
    J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity.
    Mikucki ME; Fisher DT; Ku AW; Appenheimer MM; Muhitch JB; Evans SS
    Int J Hyperthermia; 2013 Aug; 29(5):464-73. PubMed ID: 23862980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
    Peske JD; Woods AB; Engelhard VH
    Adv Cancer Res; 2015; 128():263-307. PubMed ID: 26216636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
    Tsai HF; Hsu PN
    J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic lymphocyte-mediated immunotherapy.
    Smyth MJ; Kershaw MH
    Aust N Z J Med; 1995 Dec; 25(6):852-8. PubMed ID: 8770363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
    Bonavida B; Chouaib S
    Ann Oncol; 2017 Mar; 28(3):457-467. PubMed ID: 27864216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
    Ramsay AG
    Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VISTA expressed in tumour cells regulates T cell function.
    Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
    Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.
    Kudo-Saito C; Fuwa T; Kawakami Y
    Eur J Cancer; 2016 Jul; 62():54-61. PubMed ID: 27208904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.